The prognostic role of TGF-β signaling pathway in breast cancer patients

Annals of Oncology

Volumn 24, Issue 2, 2013, Pages 384-390

  de Kruijf, E M ^a   Dekker, T J A ^a   Hawinkels, L J A C ^a   Putter, H ^a   Smit, V T H B M ^a   Kroep, J R ^a   Kuppen, P J K ^a   Van de Velde, C J H ^a   Ten Dijke, P ^a,b   Tollenaar, R A E M ^a   Mesker, W E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Breast cancer; P Smad2; Prognosis; Smad4; TGF receptor I; TGF receptor II

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; SMAD2 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

AGE DISTRIBUTION; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EVALUATION; DOWN REGULATION; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DETERMINATION; PROTEIN PHOSPHORYLATION; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; UPREGULATION;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; RECEPTOR, ERBB-2; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD4 PROTEIN; TISSUE ARRAY ANALYSIS; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 84873857204     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds333     Document Type: Article

References (28)

1. Arteaga CL, Moses HL. TGF-beta in mammary development and neoplasia. J Mammary Gland Biol Neoplasia 1996; 1(4): 327-329.
2. Massague J. TGFbeta in cancer. Cell 2008; 134(2): 215-230.
3. Zugmaier G, Ennis BW, Deschauer B et al. Transforming growth factors type beta 1 and beta 2 are equipotent growth inhibitors of human breast cancer cell lines. J Cell Physiol 1989; 141(2): 353-361.
4. Gobbi H, Dupont WD, Simpson JF et al. Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia. J Natl Cancer Inst 1999; 91(24): 2096-2101.
5. Wiercinska E, Naber HP, Pardali E et al. The TGF-beta/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system. Breast Cancer Res Treat 2011; 128 (3): 657-666.
6. Ronnov-Jessen L, Petersen OW. Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab Invest 1993; 68 (6): 696-707.
7. Tang B, Vu M, Booker T et al. TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 2003; 112(7): 1116-1124.
8. Sheen-Chen SM, Chen HS, Sheen CW et al. Serum levels of transforming growth factor beta1 in patients with breast cancer. Arch Surg 2001; 136(8): 937-940.
9. Desruisseau S, Palmari J, Giusti C et al. Determination of TGFbeta1 protein level in human primary breast cancers and its relationship with survival. Br J Cancer 2006; 94(2): 239-246.
10. Paiva CE, Drigo SA, Rosa FE et al. Absence of transforming growth factor-beta type II receptor is associated with poorer prognosis in HER2-negative breast tumours. Ann Oncol 2010; 21(4): 734-740.
11. Walker RA, Dearing SJ, Gallacher B. Relationship of transforming growth factor beta 1 to extracellular matrix and stromal infiltrates in invasive breast carcinoma. Br J Cancer 1994; 69(6): 1160-1165.
12. Figueroa JD, Flanders KC, Garcia-Closas M et al. Expression of TGF-beta signaling factors in invasive breast cancers: relationships with age at diagnosis and tumor characteristics. Breast Cancer Res Treat 2010; 121(3): 727-735.
13. van Nes JG, de Kruijf EM, Faratian D et al. COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients. Breast Cancer Res Treat 2011; 125(3): 671-685.
14. Miyaki M, Iijima T, Konishi M et al. Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene 1999; 18(20): 3098-3103.
15. Shi Y, Hata A, Lo RS et al. A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature 1997; 388(6637): 87-93.
16. Stuelten CH, Buck MB, Dippon J et al. Smad4-expression is decreased in breast cancer tissues: a retrospective study. BMC Cancer 2006; 6: 25.
17. Levy L, Hill CS. Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol Cell Biol 2005; 25(18): 8108-8125.
18. Deckers M, van Dinther M, Buijs J et al. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res 2006; 66(4): 2202-2209.
19. Davies M, Robinson M, Smith E et al. Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinocytes by TGF-beta1 involves MAPK, Smad and AP-1 signalling pathways. J Cell Biochem 2005; 95(5): 918-931.
20. Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res 2009; 19(1): 128-139.
21. Bhowmick NA, Ghiassi M, Bakin A et al. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoAdependent mechanism. Mol Biol Cell 2001; 12(1): 27-36.
22. Matsuda T, Yamamoto T, Muraguchi A et al. Cross-talk between transforming growth factor-beta and estrogen receptor signaling through Smad3. J Biol Chem 2001; 276(46): 42908-42914.
23. Yang F, Foekens JA, Yu J et al. Laser microdissection and microarray analysis of breast tumors reveal ER-alpha related genes and pathways. Oncogene 2006; 25 (9): 1413-1419.
24. Lonn P, van der Heide LP, Dahl M et al. PARP-1 attenuates Smad-mediated transcription. Mol Cell 2010; 40(4): 521-532.
25. Sterling JA, Wu L, Banerji SS. PARP regulates TGF-beta receptor type II expression in estrogen receptor-positive breast cancer cell lines. Anticancer Res 2006; 26(3A): 1893-1901.
26. Seton-Rogers SE, Lu Y, Hines LM et al. Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells. Proc Natl Acad Sci USA 2004; 101(5): 1257-1262.
27. Wilson CA, Cajulis EE, Green JL et al. HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells. Breast Cancer Res 2005; 7(6): R1058-R1079.
28. Dowdy SC, Mariani A, Janknecht R. HER2/Neu- and TAK1-mediated upregulation of the transforming growth factor beta inhibitor Smad7 via the ETS protein ER81. J Biol Chem 2003; 278(45): 44377-44384.